574P - Prognostic mRNA expression signatures in whole blood in patients with metastatic colorectal cancer treated with 3rd line cetuximab and irinotecan

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Colon and Rectal Cancer
Presenter Jakob Schou
Citation Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370
Authors J.V. Schou1, B.V. Jensen1, D.L. Nielsen1, J.A. Palshof1, E. Høgdall2, M.K. Yilmaz3, P. Pfeiffer4, J. Johansen1, S. Rossi5
  • 1Department Of Oncology, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 2Department Of Pathology, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 3Department Of Oncology, Aalborg University Hospital, 9100 - Aalborg/DK
  • 4Department Of Oncology, Odense University Hospital, 5000 - Odense C/DK
  • 5Institute Of Oncology Research, Oncology Institute of Southern Switzerland, Bellinzona/CH

Abstract

Background

Whole blood mRNA expressions have been proposed as potential useful prognostic biomarkers in patients with cancer. Few studies have evaluated circulating mRNAs in patients with metastatic colorectal cancer (mCRC). Our objective was to find prognostic mRNAs in patients with mCRC treated with 3rd line cetuximab and irinotecan

Methods

In a prospective Phase 2 study, whole blood samples were collected in PAXgene RNA tubes from 104 mCRC patients. The samples were collected before 3rd line treatment with irinotecan and cetuximab every second week. All patients had, prior to inclusion, progressed on 5FU and oxaliplatin. RNA was purified from the whole blood and hybridized to Affymetrix U133plus2 microarrays. Cox models were used and only mRNAs, adjusted with the Bonferroni method, were retained.

Results

We found that eight of the tested mRNAs had a Bonferroni adjusted p-value 

Conclusions

Our results showed an eight-mRNA risk index as prognostic for OS in patients with mCRC. Thus using mRNAs in whole blood, which is non-invasive and can be repeated throughout a treatment period, has prognostic potential as a biomarker in the clinical setting if validated in the future.

Clinical trial identification

Legal entity responsible for the study

Herlev and Gentofte Hospital

Funding

Herlev and Gentofte Hospital

Disclosure

P. Pfeiffer: Research funding: Merck Serono, Roche, Taiho, Amgen. All other authors have declared no conflicts of interest.